CeeTox’s robust, systems-biology approach has developed in vitro models with real predictive power.
We help you identify new drug candidates, chemicals, cosmetics, and consumer products that have the lowest risk for toxicity and the highest probability of success. CeeTox helps you bring safer products to market.
On January 1, 2014, the business and assets of CeeTox was acquired by the ADME-Tox Specialists, Cyprotex PLC (www.cyprotex.com) through its US subsidiary Cyprotex US, LLC (formerly Apredica, LLC). The acquisition will allow Cyprotex to expand their portfolio of services in the personal care, cosmetics and chemical industries, and customers of CeeTox will benefit from the extended range of ADME-Tox services currently offered by Cyprotex.
For more information on the acquisition, visit: http://cyprotex.com/news/575/
SenCeeTox®, Skin Sensitization Assay
The in vitro alternative to predicting the human skin sensitization potency classification of chemicals, cosmetics and ingredients.
SenCeeTox® combines markers for cell viability, Nrf2 / ARE gene expression, and direct reactivity over concentration and time and is based on known steps in the sensitization process.
The assay is highly predictive of human sensitization. In a blinded study of 67 chemicals, the assay predicted the correct in vivo sensitization category with a sensitivity and specificity of:
Sensitivity - 81%
Specificity - 92%
- General Cytotoxicity & Systemic Prediction Models>
- ADME Services
- Endocrine Disruption Services>
- Skin and Eye Toxicity Models>
- 3D Tissue Services - Irritation & Toxicity>
- Organ Specific Toxicity Models>
- Individual Assays Offered
- Services by Industry
- Dermal and Ocular Assay Testing Schedule
- Company Information
- Events / News
- Contact Us
- Useful Links